MTST (MetaStat) Other Long-Term Liabilities: $0.15 Mil (As of Feb. 2018)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is MetaStat Other Long-Term Liabilities?

MetaStat MTST Other Long-Term Liabilities is $0.15 Mil as of Feb. 2018.

MetaStat's other long-term liabilities for the quarter that ended in Feb. 2018 was $0.15 Mil.

MetaStat's quarterly other long-term liabilities declined from Aug. 2017 ($0.10 Mil) to Nov. 2017 ($0.08 Mil) but then increased from Nov. 2017 ($0.08 Mil) to Feb. 2018 ($0.15 Mil).

MetaStat's annual other long-term liabilities increased from Feb. 2016 ($0.23 Mil) to Feb. 2017 ($2.11 Mil) but then declined from Feb. 2017 ($2.11 Mil) to Feb. 2018 ($0.15 Mil).

MetaStat Other Long-Term Liabilities Related Terms

MetaStat Other Long-Term Liabilities Historical Data

* Premium members only.

The historical data trend for MetaStat's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MetaStat Other Long-Term Liabilities Chart

MetaStat Annual Data
Trend Feb09 Feb10 Feb11 Feb12 Feb13 Feb14 Feb15 Feb16 Feb17 Feb18
Other Long-Term Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.27 0.23 2.11 0.15

MetaStat Quarterly Data
May13 Aug13 Nov13 Feb14 May14 Aug14 Nov14 Feb15 May15 Aug15 Nov15 Feb16 May16 Aug16 Nov16 Feb17 May17 Aug17 Nov17 Feb18
Other Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.11 0.15 0.10 0.08 0.15

MetaStat Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

What does a Other Long-Term Liabilities of $0.15 Mil mean?
MetaStat (MTST) has a Other Long-Term Liabilities of $0.15 Mil as of Feb. 2018. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on MetaStat and its competitors.
Is MetaStat's Other Long-Term Liabilities too high?
MetaStat's current Other Long-Term Liabilities is $0.15 Mil.
How does MetaStat's Other Long-Term Liabilities compare to OBMP and NSPX?
MetaStat's Other Long-Term Liabilities of $0.15 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long-Term Liabilities for a Biotechnology company?
A good Other Long-Term Liabilities depends on the Biotechnology industry context. However, Other Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long-Term Liabilities mean?
A high Other Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on MetaStat and its competitors. MetaStat's current Other Long-Term Liabilities is $0.15 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MetaStat stock overvalued right now?
MetaStat (MTST) has a current Other Long-Term Liabilities of $0.15 Mil. The current Other Long-Term Liabilities is $0.15 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long-Term Liabilities calculated?
Other Long-Term Liabilities is calculated from a company's financial statements. For MetaStat (MTST), the current Other Long-Term Liabilities is $0.15 Mil as of Feb. 2018. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MetaStat Business Description

Address 27 Drydock Avenue, 2nd Floor, Boston, MA, USA, 02210
MetaStat Inc is a us-based biotechnology company which focuses on discovering and developing personalized therapeutic (Rx) and diagnostic (Dx) treatment solutions for cancer patients. The company focuses on development programs of the novel therapeutic product candidates that target the Mena protein isoform whereas the Companion Diagnostics program is focused on developing companion tests to be used in combination with cancer drugs, that provide essential information for the safe and effective use of a corresponding drug or biological product to improve patient outcome. It also develops a prognostic diagnostic program which is focused on developing diagnostic tests that predict the risk of future metastasis in cancer patients following the initial treatment of their primary tumor.